PRVA (Privia Health Group) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Privia Health Group Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Privia Health Group is: Moderate Risk: Sensitive, better choose undervalued stock.

Competitive Comparison of Privia Health Group's Risk Assessment

For the Health Information Services subindustry, Privia Health Group's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Privia Health Group's Risk Assessment Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Privia Health Group's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Privia Health Group's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Privia Health Group (NAS:PRVA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Privia Health Group Risk Assessment Related Terms

Thank you for viewing the detailed overview of Privia Health Group's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Privia Health Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Privia Health Group Inc (NAS:PRVA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

950 North Glebe Road, Suite 700, Arlington, VA, USA, 22203

Website

https://www.priviahealth.com

Privia Health Group Inc is a technology-driven, national physician-enablement company. It collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual care settings.

Executives

Parth Mehrotra	officer: President and COO	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
David Mountcastle	officer: Chief Financial Officer	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203
Adam Boehler	director	1215 5TH AVE N,, NASHVILLE TN 37208
Thomas A Mccarthy	director	1601 CHESTNUT STREET, SHAREHOLDER SERVICES TL18Y, PHILADELPHIA PA 19192
Thomas Bartrum	officer: EVP, General Counsel	950 N. GLEBE RD., SUITE 700, ALEXANDRIA VA 22203
Matthew Shawn Morris	director, officer: Chief Executive Officer	950 N. GLEBE ST., SUITE 700, ARLINGTON VA 22203
William M Sullivan	director	ONE PENN PLAZA, SUITE 5300, NY NY 10119
Pamela O Kimmet	director	11207 ORANGE HIBISCUS LANE, PALM BEACH GARDENS FL 33418
David S Wichmann	director	BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752
Goldman Sachs Group Inc	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Jeffrey Daniel Bernstein	director	200 WEST STREET, NEW YORK NY 10282
Pamplona Capital Partners Iii, L.p.	10 percent owner	94 SOLARIS AVENUE, CAMANA BAY, P.O. BOX 1348, GRAND CAYMAN E9 KY1-1108
Mbd Advisors, L.l.c.	10 percent owner	200 WEST STREET, NEW YORK NY 10282
Jeffrey B Butler	director	950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22101
David P King	director	PRIVIA HEALTH GROUP, INC., 950 N. GLEBE RD., SUITE 700, ARLINGTON VA 22203